Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • Tenofovir AF a novel prodrug of tenofovir that results in lower plasma concentrations and higher intracellular concentrations of tenofovir relative to tenofovir DF[Ruane 2013]
  • Tenofovir AF has superior antiviral efficacy through 144 weeks and reduced bone toxicity when compared with tenofovir DF[Sax 2015; Arribas 2017]

Action required

Keywords: Bone Disease , Treatment Complications

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.